Mangoceuticals Capital Raise
Mangoceuticals, Inc. received written consent from its Series B Preferred Stock holder to establish a new series of 8% Series D Convertible Cumulative Preferred Stock. The company plans to offer up to 1,000,000 shares of the Series D Preferred Stock at $10.00 per share through a Regulation A offering. The Series B holder also approved an amendment to recognize the senior dividend and liquidation rights of the new Series D shares.